[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

Stocks with 5 days of consecutive price advances. If you cannot see this email properly, please click [here]( [marketinside...] --------------------------------------------------------------- Sponsor Message [How High Can Copper Go?]( [Find Out in this Research Report.]([aff_i?offer_...] --------------------------------------------------------------- November 15, 2022 From the desk of the Editor (5 Day Gainers Report) Dear Reader, We just identified 7 Five Day Gainers across all US Exchanges. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- Sponsor Message [New "Vertical" Technology Solves Solar Power's Major Flaw]( [43705a26-d32...](Even conservationists hate conventional solar farms. That's because they take up too much land and can degrade the environment. And let's face it, land is expensive... Fortunately, new groundbreaking tower technology solves solar's #1 drawback. These unique vertical structures not only take up to 90% less land space, but also generate extra electric power. [See How Early Stage Investors in This Solar Tech Could Benefit]( [5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- [4D Molecular Therapeutics, FDMT]( Recent Analyst Action: Joshua Schimmer, analyst at Evercore ISI, reiterates coverage on [4D Molecular Therapeutics (FDMT)](in the Healthcare sector with a Buy rating and a price target of $45.00 (1 day ago). - Recent Price: $16.75 - Average Analyst Price Target: $28.33 (69.13%) - Market Cap: $405.23M [TipRanks.com]( also reports that [4D Molecular Therapeutics](currently has 3 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $28.33. The target pricing ranges from a high forecast of $45.00 down to a low forecast of $15.00. [4D Molecular Therapeutics (FDMT)](’s last closing price was $16.75 which would put the average price target at $28.33. Here are 3rd party ratings for [FDMT](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak buy - Zacks.com: Hold, Top 36% (91 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Millionaire Investor Reveals: "How I Made My Second Fortune... By Avoiding 99% of Stocks"]( [eb528704-62b...](Buy this small group of unique stocks… never sell them… and make all the money you need… No matter what happens in the market. [Revealed here: the name and ticker of the #1 stock.]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Outset Medical, OM]( Recent Analyst Action: Shagun Singh, analyst at RBC Capital, reiterates coverage on [Outset Medical (OM)](in the Healthcare sector with a Buy rating and a price target of $23.00 (4 days ago). - Recent Price: $19.78 - Average Analyst Price Target: $22.75 (15.02%) - Market Cap: $863.74M [TipRanks.com]( also reports that [Outset Medical](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $22.75. The target pricing ranges from a high forecast of $29.00 down to a low forecast of $17.00. [Outset Medical (OM)](’s last closing price was $19.78 which would put the average price target at $22.75. Here are 3rd party ratings for [OM](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Sell, Top 34% (86 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- [Tenaya Therapeutics, TNYA]( Recent Analyst Action: Geulah Livshits, analyst at Chardan Capital, reiterates coverage on [Tenaya Therapeutics (TNYA)](in the Healthcare sector with a Buy rating and a price target of $28.00 (4 days ago). - Recent Price: $3.05 - Average Analyst Price Target: $24.50 (703.28%) - Market Cap: $110.47M [TipRanks.com]( also reports that [Tenaya Therapeutics](currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $24.50. The target pricing ranges from a high forecast of $28.00 down to a low forecast of $21.00. [Tenaya Therapeutics (TNYA)](’s last closing price was $3.05 which would put the average price target at $24.50. Here are 3rd party ratings for [TNYA](: - TipRanks.com: Strong Buy - TradingView.com: Neutral - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Top 25% (62 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message ["Financial Nostradamus" makes bone-chilling prediction...]( [3b7bccb1-06a...](In 2019, [this man]( wrote a book called Aftermath that shocked the world by predicting that “Something on the scale of a global pandemic will be the cause of the next financial crisis” And that “it will happen with 100% certainty” in the next few years. Just four months later we had the first reported case of the coronavirus. Now he’s back with another [bone-chilling prediction.]( A prediction that’s already starting to come true. A prediction I’m urging you to watch right away. Because if what he says is true, within days this single event will have a profound effect on your retirement assets, your banks account and your entire way of life. [Click Here to See This Exclusive Interview]( Warning: What you’re about to see is a REAL exclusive interview with a former CIA and Pentagon insider. The content herein is NOT for the faint of heart. [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Quanterix, QTRX]( Recent Analyst Action: Matthew Sykes, analyst at Goldman Sachs, reiterates coverage on [Quanterix (QTRX)](in the Healthcare sector with a Hold rating and a price target of $13.00 (5 days ago). - Recent Price: $13.12 - Average Analyst Price Target: $13.75 (4.80%) - Market Cap: $469.85M [TipRanks.com]( also reports that [Quanterix](currently has 4 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $13.75. The target pricing ranges from a high forecast of $15.00 down to a low forecast of $12.00. [Quanterix (QTRX)](’s last closing price was $13.12 which would put the average price target at $13.75. Here are 3rd party ratings for [QTRX](: - TipRanks.com: Hold - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Sell, Bottom 36% (161 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- [Avita Medical, RCEL]( Recent Analyst Action: Ryan Zimmerman, analyst at BTIG, reiterates coverage on [Avita Medical (RCEL)](in the Healthcare sector with a Buy rating and a price target of $16.00 (5 days ago). - Recent Price: $7.5 - Average Analyst Price Target: $13.50 (80.00%) - Market Cap: $175.22M [TipRanks.com]( also reports that [Avita Medical](currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $13.50. The target pricing ranges from a high forecast of $16.00 down to a low forecast of $11.00. [Avita Medical (RCEL)](’s last closing price was $7.5 which would put the average price target at $13.50. Here are 3rd party ratings for [RCEL](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Buy, Top 36% (91 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Copper More Critical than Lithium?]( [be7e813c-17c...](Lithium may have grabbed the headlines as a key material in building electric vehicles (EVs). But so is copper. And copper's importance in the new green economy goes far beyond EVs. Copper is critical in building wind turbines and solar panels. It's key to power lines and upgrading the national grid. Analysts say we're facing a 10-million-ton shortfall if new copper mines are not found. [See How You Can Benefit From New Copper Discoveries.]( [5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- [Olaplex Holdings, OLPX]( Recent Analyst Action: Dara Mohsenian, analyst at Morgan Stanley, reiterates coverage on [Olaplex Holdings (OLPX)](in the Consumer Goods sector with a Hold rating and a price target of $6.00 (5 days ago). - Recent Price: $6.15 - Average Analyst Price Target: $8.64 (40.49%) - Market Cap: $3.77B [TipRanks.com]( also reports that [Olaplex Holdings](currently has 12 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $8.64. The target pricing ranges from a high forecast of $17.00 down to a low forecast of $5.00. [Olaplex Holdings (OLPX)](’s last closing price was $6.15 which would put the average price target at $8.64. Here are 3rd party ratings for [OLPX](: - TipRanks.com: Hold - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Sell, Bottom 29% (179 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- [Flux Power Holdings, FLUX]( Recent Analyst Action: Amit Dayal, analyst at H.C. Wainwright, reiterates coverage on [Flux Power Holdings (FLUX)](in the Services sector with a Buy rating and a price target of $15.00 (4 days ago). - Recent Price: $5 - Average Analyst Price Target: $10.50 (110.00%) - Market Cap: $75.51M [TipRanks.com]( also reports that [Flux Power Holdings](currently has 2 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $10.50. The target pricing ranges from a high forecast of $15.00 down to a low forecast of $6.00. [Flux Power Holdings (FLUX)](’s last closing price was $5 which would put the average price target at $10.50. Here are 3rd party ratings for [FLUX](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Buy, Top 35% (89 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Apple, Amazon, and Walmart are Investing in Solar Energy]( [4f9b70f4-98c...](The global market for solar energy is expected to be worth an astronomical $1 trillion by the end of 2028, with increasing adoption of solar by commercial, non-profit, and public entities. Even Fortune 500 companies such as Apple, Amazon, and Walmart are investing in solar to help save money over the long term. So it's little wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market. [See How Investors Could Benefit]( [5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- And there you have it--7 Five Day Gainers across all US Exchanges. Sincerely, The Editor, MarketInsidersPress.com Market Insider Press Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. MarketInsidersPress.com part of Sandpiper Marketing Group, LLC 165 Lockerbie Lane | Mooresville NC | 28115 MarketInsidersPress.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mount Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software